BPC-157 Dosage Guide: Oral vs Injection, Loading vs Maintenance (2026)

What Is BPC-157? A Quick Overview

BPC-157, short for Body Protection Compound-157, is a synthetic pentadecapeptide consisting of 15 amino acids with a molecular weight of 1,419.55 daltons. It is derived from a larger protective protein naturally found in human gastric juice (Sikiric et al., 2018).

What makes BPC-157 relevant to a dosage discussion is its unusual pharmacological profile:

• Gastric acid stability: Unlike virtually every other peptide, BPC-157 survives in human gastric juice for over 24 hours (Sikiric et al., 2011).
• No identified toxic dose: In preclinical studies, researchers have been unable to establish a lethal dose, indicating an exceptionally wide safety margin (Seiwerth et al., 2018).
• Equipotent dosing across routes: The same dose range appears to produce comparable effects whether by injection or by mouth (Sikiric et al., 2021).
• Short half-life: Elimination half-life is less than 30 minutes after intramuscular administration (Xu et al., 2022).

Understanding BPC-157 Dosage Ranges

What the Animal Studies Use

The majority of BPC-157 research uses two dose levels: 10 mcg/kg (most commonly used) and 10 ng/kg (a much lower dose that has also shown activity). 10 mcg/kg represents the standard reference dose (Sikiric et al., 2018).

Translating to Human Equivalent Doses

Using the FDA’s body surface area conversion (rat factor: 0.162), for a 75 kg person:

The proposed clinical dose was specifically stated as 200 mcg/person/day (Xu et al., 2022).

Common Dosage Ranges

Injection vs Oral BPC-157 Dosage

Subcutaneous Injection

Subcutaneous (SubQ) injection is the most commonly discussed route. The peptide is injected into the fatty tissue layer just beneath the skin using an insulin syringe (29-31 gauge needle).

Key characteristics:

• Bioavailability: Higher than oral. Pharmacokinetic data showed intramuscular bioavailability of approximately 14-19% in rats, approximately 45-51% in dogs (Xu et al., 2022).
• Local vs systemic: When injected near an injury site, higher local concentration reaches the target tissue. Abdominal injection provides more systemic distribution.
• Typical dose: 200-500 mcg per injection, once or twice daily.

Injection Site Considerations

For injection technique details, see How to Inject Peptides.

Oral and Sublingual Administration

BPC-157’s gastric acid stability makes it one of the only peptides that can be taken orally. In human gastric juice, BPC-157 remains stable for over 24 hours (Sikiric et al., 2011).

• Bioavailability: Lower than injection but still sufficient for systemic effects based on animal studies.
• Best for: Gut-related concerns, individuals who want to avoid injections, general systemic support.
• Typical dose: 250-500 mcg per dose, once or twice daily. Some protocols use higher oral doses (up to 500-800 mcg).

Route Comparison Table

Loading vs Maintenance Phases

Loading Phase

The loading phase uses a higher daily dose for the first 1-4 weeks. The rationale is that a higher initial dose may establish tissue-level saturation more quickly.

• Dose: 400-800 mcg/day (often split into two doses of 200-400 mcg)
• Frequency: Twice daily (morning and evening)
• Duration: 1-4 weeks

Maintenance Phase

• Dose: 200-300 mcg/day (single dose or split)
• Frequency: Once daily
• Duration: 4-8 additional weeks (total protocol 6-12 weeks)

Example Protocol Timelines

BPC-157 Reconstitution Math

The formula: Concentration (mcg per unit) = Total peptide (mcg) / Total volume of water (units)

When using an insulin syringe, 1 mL = 100 units.

5 mg (5,000 mcg) Vial Reference

10 mg (10,000 mcg) Vial Reference

Reconstitution Best Practices

• Always use bacteriostatic water (not sterile water, saline, or tap water).
• Add water slowly along the inside wall of the vial.
• Swirl gently — never shake.
• Refrigerate after reconstitution at 2-8°C.
• Use within 28-30 days. Mark the date on the vial.

For the full process, see How to Reconstitute Peptides.

Timing and Frequency

Once Daily vs Twice Daily

Timing Around Meals (Oral BPC-157)

On an empty stomach (30-60 minutes before or 2 hours after a meal) is most commonly recommended. This minimizes competition with food proteins for absorption. For gut-specific concerns, empty-stomach dosing provides the most direct contact between BPC-157 and the gastrointestinal lining.

BPC-157 Cycle Length

Common cycling patterns: 8 weeks on / 4 weeks off, 12 weeks on / 4-6 weeks off, or as-needed cycles.

Common BPC-157 Dosage Mistakes

1. Confusing Micrograms (mcg) and Milligrams (mg)

The difference is a factor of 1,000. A 5 mg vial contains 5,000 mcg. A typical dose is 250 mcg, not 250 mg. Always double-check the unit.

2. Not Accounting for Reconstitution Volume

Adding different amounts of water changes concentration: 5 mg + 1 mL = 50 mcg/unit, but 5 mg + 2 mL = 25 mcg/unit. Always calculate your specific concentration before drawing any dose.

3. Using Too Little Water

Very small amounts of water create highly concentrated solutions, making precise dosing difficult. Using 1-2 mL for a 5 mg vial is a good balance.

4. Inconsistent Dosing Schedule

BPC-157’s short half-life means tissue levels drop quickly. Skipping days produces inconsistent exposure. Use consistent, scheduled dosing.

5. Stopping Too Early

Tissue repair takes weeks to months. Running a protocol for only 1-2 weeks may mean stopping before results can appear. Minimum 4 weeks, standard 6-8 weeks.

6. Ignoring Storage Requirements

Reconstituted BPC-157 must be refrigerated. Leaving it at room temperature — even for a day — can degrade it significantly.

7. Drawing From a Vial With a Used Needle

Always use a fresh needle to draw from the vial. Re-inserting a used needle introduces bacteria and compromises remaining doses.

Safety Considerations

BPC-157 has demonstrated an unusually favorable safety profile. Formal toxicology found no serious toxicity in mice, rats, rabbits, or dogs. No genotoxicity, no embryo-fetal toxicity. In dogs, it was well tolerated at doses up to 2 mg/kg — roughly 200-300 times the typical research dose (Xu et al., 2020).

BPC-157 has also been used in early-phase clinical trials for ulcerative colitis and multiple sclerosis, with no reported toxicity (Sikiric et al., 2021).

Important caveats: Long-term human safety data is not available. BPC-157 promotes angiogenesis — a theoretical concern for individuals with existing tumors. Individual responses can vary.

For a broader discussion, see Are Peptides Safe?

Frequently Asked Questions

What is the standard BPC-157 dosage?

The most commonly referenced dosage is 250-500 mcg per day, based on allometric scaling from the standard animal research dose of 10 mcg/kg body weight. This can be a single daily dose or split into two doses.

Is injection or oral BPC-157 better?

Neither is categorically “better.” Subcutaneous injection near an injury site may provide higher local tissue concentration. Oral BPC-157 provides direct contact with the gastrointestinal lining and avoids injections. Research describes comparable effects from both routes at equivalent doses in animal models (Sikiric et al., 2011).

How do I calculate my BPC-157 dose?

Use this formula: Dose in units = Desired dose (mcg) / Concentration (mcg per unit). A 5 mg vial with 2 mL water gives 25 mcg per unit. For a 250 mcg dose, draw 10 units.

Should I use a loading phase?

A loading phase is discussed in some protocols but is not universally recommended. Many practitioners use consistent daily dosing from day one. No published research directly compares loading vs non-loading approaches for BPC-157.

How long should a BPC-157 cycle last?

Most protocols run 4-12 weeks, with 6-8 weeks being most common. Some practitioners recommend cycling off for 4-6 weeks between protocols.

Can I take BPC-157 with other peptides?

BPC-157 is frequently discussed in combination with TB-500 (the “Wolverine Stack”). Standard dosing for each is typically maintained when used together. No clinical trials have tested peptide combinations in humans. See BPC-157 vs TB-500.

Is BPC-157 safe at higher doses?

Preclinical evaluations show BPC-157 well tolerated at doses far exceeding typical research ranges. No lethal dose has been identified (Xu et al., 2020). However, long-term human safety at any dose has not been established.

Does BPC-157 need to be injected near the injury site?

Injecting near the site of concern is a common recommendation for musculoskeletal issues. However, BPC-157 also demonstrates systemic effects when injected at distant sites or taken orally. Animal studies showed positive outcomes with intraperitoneal injection (Chang et al., 2011).

Related Articles

• BPC-157 Benefits and Research
• How to Reconstitute Peptides
• How to Inject Peptides: Complete Guide
• BPC-157 vs TB-500: Full Comparison
• Peptide Calculator